CD63

Across TCGA pan-cancer cohorts, CD63 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CD63’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD63 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD63 is over-expressed in tumor, although a few such as LUSC and PRAD show the opposite, repressed pattern.

KIRC, KIRP, and THCA are the cancer types where CD63 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD63 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.117	<.001	12	view →
KIRP	Male	III,IV	+1.551	<.001	11	view →
THCA	Female	II,III,IV	+0.913	<.001	10	view →
LIHC	Female	II,III,IV	+1.479	<.001	9	view →
LUSC	Female	All	−0.877	<.001	8	view →
CHOL	All	All	+1.956	<.001	3	view →
HNSC	All	III,IV	+0.498	.009	3	view →
STAD	All	All	+0.373	.014	3	view →
ESCA	All	All	+0.782	.011	2	view →
PRAD	All	All	−0.200	.030	2	view →
KICH	Male	IV	+0.613	.046	1	view →
READ	Female	All	−0.610	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CD63–KIRC

Open the KIRC breakdown →